1. Home
  2. ZNTL vs SAR Comparison

ZNTL vs SAR Comparison

Compare ZNTL & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.21

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$13.58

Market Cap

233.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZNTL
SAR
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
289.0M
233.9M
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
ZNTL
SAR
Price
$2.21
$13.58
Analyst Decision
Buy
Hold
Analyst Count
11
7
Target Price
$7.44
★ $20.00
AVG Volume (30 Days)
★ 1.3M
163.5K
Earning Date
11-09-2026
10-06-2026
Dividend Yield
N/A
★ 21.64%
EPS Growth
★ 18.03
14.36
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$0.78
Revenue Next Year
N/A
$6.28
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.21
$13.52
52 Week High
$6.95
$24.07

Technical Indicators

Market Signals
Indicator
ZNTL
SAR
Relative Strength Index (RSI) 33.89 22.01
Support Level $2.09 N/A
Resistance Level $2.76 $23.85
Average True Range (ATR) 0.17 0.60
MACD 0.03 -0.11
Stochastic Oscillator 17.35 7.07

Price Performance

Historical Comparison
ZNTL
SAR

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

Share on Social Networks: